These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

546 related items for PubMed ID: 21885917

  • 1. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
    Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kálai T, Hideg K, Kuppusamy P.
    Cancer Biol Ther; 2011 Nov 01; 12(9):837-45. PubMed ID: 21885917
    [Abstract] [Full Text] [Related]

  • 2. Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer.
    ElNaggar AC, Saini U, Naidu S, Wanner R, Sudhakar M, Fowler J, Nagane M, Kuppusamy P, Cohn DE, Selvendiran K.
    Cancer Biol Ther; 2016 Oct 02; 17(10):1107-1115. PubMed ID: 27415751
    [Abstract] [Full Text] [Related]

  • 3. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
    Bixel K, Saini U, Kumar Bid H, Fowler J, Riley M, Wanner R, Deepa Priya Dorayappan K, Rajendran S, Konishi I, Matsumura N, Cohn DE, Selvendiran K.
    Int J Cancer; 2017 Nov 01; 141(9):1856-1866. PubMed ID: 28646535
    [Abstract] [Full Text] [Related]

  • 4. HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells.
    Tierney BJ, McCann GA, Cohn DE, Eisenhauer E, Sudhakar M, Kuppusamy P, Hideg K, Selvendiran K.
    Cancer Biol Ther; 2012 Jul 01; 13(9):766-75. PubMed ID: 22801507
    [Abstract] [Full Text] [Related]

  • 5. Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts.
    Selvendiran K, Tong L, Bratasz A, Kuppusamy ML, Ahmed S, Ravi Y, Trigg NJ, Rivera BK, Kálai T, Hideg K, Kuppusamy P.
    Mol Cancer Ther; 2010 May 01; 9(5):1169-79. PubMed ID: 20442315
    [Abstract] [Full Text] [Related]

  • 6. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M, Qi Z, Liu B, Ren Y, Li H, Yang G, Zhang Q.
    Oncotarget; 2015 Sep 22; 6(28):25281-94. PubMed ID: 26325371
    [Abstract] [Full Text] [Related]

  • 7. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts.
    Selvendiran K, Bratasz A, Tong L, Ignarro LJ, Kuppusamy P.
    Cell Cycle; 2008 Jan 01; 7(1):81-8. PubMed ID: 18196976
    [Abstract] [Full Text] [Related]

  • 8. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog.
    Abuzeid WM, Davis S, Tang AL, Saunders L, Brenner JC, Lin J, Fuchs JR, Light E, Bradford CR, Prince ME, Carey TE.
    Arch Otolaryngol Head Neck Surg; 2011 May 01; 137(5):499-507. PubMed ID: 21576562
    [Abstract] [Full Text] [Related]

  • 9. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
    Han Z, Hong Z, Gao Q, Chen C, Hao Z, Ji T, Hu W, Yan Y, Feng J, Liao S, Wu P, Wang D, Wang S, Zhou J, Ma D.
    Hum Gene Ther; 2012 Jan 01; 23(1):32-45. PubMed ID: 21875334
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma.
    Lau CK, Yang ZF, Lam SP, Lam CT, Ngai P, Tam KH, Poon RT, Fan ST.
    Cancer Biol Ther; 2007 Dec 01; 6(12):1900-7. PubMed ID: 18059167
    [Abstract] [Full Text] [Related]

  • 11. HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer.
    Rath KS, Naidu SK, Lata P, Bid HK, Rivera BK, McCann GA, Tierney BJ, Elnaggar AC, Bravo V, Leone G, Houghton P, Hideg K, Kuppusamy P, Cohn DE, Selvendiran K.
    Cancer Res; 2014 Apr 15; 74(8):2316-27. PubMed ID: 24590057
    [Abstract] [Full Text] [Related]

  • 12. Ghrelin enhances cisplatin sensitivity in HO-8910 PM human ovarian cancer cells.
    Leng Y, Zhao C, Yan G, Xu S, Yang Y, Gong T, Li X, Li C.
    J Ovarian Res; 2021 Nov 17; 14(1):162. PubMed ID: 34789301
    [Abstract] [Full Text] [Related]

  • 13. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression.
    Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, Hideg K, Kuppusamy P.
    J Biol Chem; 2007 Sep 28; 282(39):28609-28618. PubMed ID: 17684018
    [Abstract] [Full Text] [Related]

  • 14. NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
    Bratasz A, Selvendiran K, Wasowicz T, Bobko A, Khramtsov VV, Ignarro LJ, Kuppusamy P.
    J Transl Med; 2008 Feb 26; 6():9. PubMed ID: 18302761
    [Abstract] [Full Text] [Related]

  • 15. A novel curcumin analog (H-4073) enhances the therapeutic efficacy of cisplatin treatment in head and neck cancer.
    Kumar B, Yadav A, Hideg K, Kuppusamy P, Teknos TN, Kumar P.
    PLoS One; 2014 Feb 26; 9(3):e93208. PubMed ID: 24675768
    [Abstract] [Full Text] [Related]

  • 16. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
    Ji T, Gong D, Han Z, Wei X, Yan Y, Ye F, Ding W, Wang J, Xia X, Li F, Hu W, Lu Y, Wang S, Zhou J, Ma D, Gao Q.
    Cancer Lett; 2013 Dec 01; 341(2):231-9. PubMed ID: 23962558
    [Abstract] [Full Text] [Related]

  • 17. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
    Tang YJ, Sun ZL, Wu WG, Xing J, He YF, Xin DM, Han P.
    Genet Mol Res; 2015 Mar 30; 14(1):2450-60. PubMed ID: 25867391
    [Abstract] [Full Text] [Related]

  • 18. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion.
    Wang H, Luo Y, Qiao T, Wu Z, Huang Z.
    J Ovarian Res; 2018 Nov 19; 11(1):93. PubMed ID: 30454003
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J, Shi HR, Ren F, Wang JL, Wu QH, Li X, Zhang RT.
    BMC Cancer; 2017 Dec 14; 17(1):851. PubMed ID: 29241458
    [Abstract] [Full Text] [Related]

  • 20. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
    Shen W, Liang B, Yin J, Li X, Cheng J.
    Cell Biochem Biophys; 2015 May 14; 72(1):203-13. PubMed ID: 25510462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.